Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis.
Nat. Genet., Nov;44(12):1349-54 (2012)
Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease.
Am. J. Med. Genet. B Neuropsychiatr. Genet., Oct;159B(7):874-83 (2012)
Increased Î²-amyloid deposition in Tg-SWDI transgenic mouse brain following in vivo lead exposure.
Toxicol. Lett., Sep;213(2):211-9 (2012)
Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine.
Dement Geriatr Cogn Disord., 33(2-3):164-73 (2012)
ADAM10 expression and promoter haplotype in Alzheimer's disease.
Neurobiol. Aging., Sep;33(9):2229.e1-2229.e9 (2012)
Genotype patterns at PICALM, CR1, BIN1, CLU, and APOE genes are associated with episodic memory.
Neurology., May;78(19):1464-71 (2012)
Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity.
J. Biol. Chem., Apr;287(16):12858-66 (2012)
Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans.
Proc. Natl. Acad. Sci. U.S.A., Mar;109(10):3985-90 (2012)
Caffeic acid phenethyl ester extends survival of a mouse model of amyotrophic lateral sclerosis.
Neuroscience., Mar;205:185-93 (2012)
Reviewing the role of donepezil in the treatment of Alzheimer's disease.
Curr Alzheimer Res., Sep;9(7):773-81 (2012)
The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule treatment in Alzheimer's disease.
Dement Geriatr Cogn Dis Extra., Jan;1(1):150-62 (2011)
Association of clusterin gene polymorphisms with late-onset Alzheimer's disease.
Dement Geriatr Cogn Disord., 32(3):198-201 (2011)
Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Int J Geriatr Psychiatry., Dec;26(12):1236-43 (2011)
RAPID progression: tool for screening aggressive course of disease (ACD) in Alzheimer dementia.
J Med Assoc Thai., Apr;94(4):485-9 (2011)
Caffeic acid phenethyl ester prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration.
Neuroscience., Aug;188:135-41 (2011)
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.
Nat. Genet., May;43(5):436-41 (2011)
Transdermal patches for the treatment of neurologic conditions in elderly patients: a review.
Prim Care Companion CNS Disord., 13(6) (2011)
Lead exposure increases levels of Î²-amyloid in the brain and CSF and inhibits LRP1 expression in APP transgenic mice.
Neurosci. Lett., Feb;490(1):16-20 (2011)
Validation of consensus panel diagnosis in dementia.
Arch. Neurol., Dec;67(12):1506-12 (2010)
Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors.
Arch. Neurol., Mar;68(3):329-37 (2011)
Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia.
CNS Neurosci Ther., Dec;16(6):330-6 (2010)
The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease.
Curr Med Res Opin., Oct;26(10):2441-7 (2010)
Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
Clin Ther., Jul;32(7):1234-51 (2010)
Differences in medication use in the Alzheimer's disease neuroimaging initiative: analysis of baseline characteristics.
Drugs Aging., Aug;27(8):677-86 (2010)
Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease?
Alzheimers Res Ther., 2(3):15 (2010)
Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.
Dement Geriatr Cogn Disord., 29(5):406-12 (2010)
Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease.
Am J Alzheimers Dis Other Demen., Jun;25(4):347-52 (2010)
Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.
Clin Neuropharmacol., 33(2):67-73 (2010 Mar-Apr)
Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.
Clin Drug Investig., 30(1):41-9 (2010)
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
Curr Med Res Opin., Feb;26(2):263-9 (2010)
Correlation of clinical features with argyrophilic grains at autopsy.
Alzheimer Dis Assoc Disord., 23(3):229-33 (2009 Jul-Sep)
PET of brain prion protein amyloid in Gerstmann-StrÃ¤ussler-Scheinker disease.
Brain Pathol., Mar;20(2):419-30 (2010)
Adipose stromal cells-secreted neuroprotective media against neuronal apoptosis.
Neurosci. Lett., Oct;462(1):76-9 (2009)
Duplication within the SEPT9 gene associated with a founder effect in North American families with hereditary neuralgic amyotrophy.
Hum. Mol. Genet., Apr;18(7):1200-8 (2009)
The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease.
Lancet Neurol., Jan;8(1):22-3 (2009)
IFATS collection: The conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats.
Stem Cells., Feb;27(2):478-88 (2009)
Randomized clinical trial results for donepezil in Alzheimer's disease: is the treatment glass half full or half empty?
J Am Geriatr Soc., Aug;56(8):1566-7 (2008)
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.
Arch. Neurol., Aug;65(8):1031-8 (2008)
Caffeic acid phenethyl ester prevents cerebellar granule neurons (CGNs) against glutamate-induced neurotoxicity.
Neuroscience., Sep;155(4):1098-105 (2008)
Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials.
Drug Saf., 31(7):577-85 (2008)
Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels.
J. Alzheimers Dis., Apr;13(3):255-66 (2008)
Treatment options in Alzheimer's disease: maximizing benefit, managing expectations.
Dement Geriatr Cogn Disord., 25(5):408-22 (2008)
Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease.
Pharmacogenet. Genomics., Apr;18(4):289-98 (2008)
In vivo and postmortem clinicoanatomical correlations in frontotemporal dementia and parkinsonism linked to chromosome 17.
Neurodegener Dis., 5(3-4):215-7 (2008)
A modern hypothesis: The distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease.
Dement Geriatr Cogn Disord., 25(4):301-8 (2008)
Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase.
Clin Neuropharmacol., 30(6):317-25 (2007 Nov-Dec)
The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family.
Brain., Jan;131(Pt 1):72-89 (2008)
Association of statin use with cognitive decline in elderly African Americans.
Neurology., Nov;69(19):1873-80 (2007)
Rivastigmine three times daily improves cognition and response in Alzheimer's disease.
Evid Based Ment Health., Nov;10(4):116 (2007)
Depressed mood in informal caregivers of individuals with mild cognitive impairment.
Am J Alzheimers Dis Other Demen., 22(4):273-85 (2007 Aug-Sep)
Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry.
Brief Funct Genomic Proteomic., Jun;6(2):149-58 (2007)
Effective pharmacologic management of Alzheimer's disease.
Am. J. Med., May;120(5):388-97 (2007)
Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
Am J Geriatr Pharmacother., 4 Suppl A:S9-S24; quiz S25-S28 (2006)
Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.
Rapid Commun. Mass Spectrom., 20(24):3723-35 (2006)
Use of antidementia agents in vascular dementia: beyond Alzheimer disease.
Mayo Clin. Proc., Oct;81(10):1350-8 (2006)
High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression.
J. Child Neurol., Jun;21(6):444-9 (2006)
Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition.
Arch. Neurol., Jul;63(7):936-9 (2006)
Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?
Alzheimers Dement., Apr;2(2):118-25 (2006)
Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.
Neurology., Feb;66(4):602-4 (2006)
A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type.
Curr Alzheimer Res., Dec;2(5):541-51 (2005)
Safety and acceptability of the research lumbar puncture.
Alzheimer Dis Assoc Disord., 19(4):220-5 (2005 Oct-Dec)
Caffeic acid phenethyl ester possesses potent cardioprotective effects in a rabbit model of acute myocardial ischemia-reperfusion injury.
Am. J. Physiol. Heart Circ. Physiol., Nov;289(5):H2265-71 (2005)
The use of memantine in dementia with Lewy bodies.
J. Alzheimers Dis., Aug;7(4):285-9 (2005)
Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis.
Dement Geriatr Cogn Disord., 20(2-3):192-7 (2005)
Combination drug therapies for AD: progress is slow, but we must keep trying.
Geriatrics., Jun;60(6):13-4 (2005)
NF-(kappa)B mediates amyloid beta peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells.
Brain Res. Mol. Brain Res., May;136(1-2):177-88 (2005)
Utilizing combination therapy in the treatment of Alzheimer's disease.
Expert Rev Neurother., Sep;4(5):799-808 (2004)
Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study.
Prim Care Companion J Clin Psychiatry., 7(2):43-48 (2005)
Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease.
J. Lipid Res., May;46(5):949-68 (2005)
Minocycline prevents gentamicin-induced ototoxicity by inhibiting p38 MAP kinase phosphorylation and caspase 3 activation.
Neuroscience., 131(2):513-21 (2005)
Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years.
BMC Geriatr., 5:3 (2005)
Impact of APOE in mild cognitive impairment.
Neurology., Nov;63(10):1898-901 (2004)
Caffeic acid phenethyl ester prevents neonatal hypoxic-ischaemic brain injury.
Brain., Dec;127(Pt 12):2629-35 (2004)
NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.
Geriatrics., Jun;59(6):22-7 (2004)
Cholesterol and APOE genotype interact to influence Alzheimer disease progression.
Neurology., May;62(10):1869-71 (2004)
On the horizon: pathways for drug development in Alzheimer's disease.
Clin. Geriatr. Med., Feb;20(1):141-52 (2004)
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
JAMA., Jan;291(3):317-24 (2004)
Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.
Curr Med Res Opin., 19(8):707-14 (2003)
Clinical pharmacokinetics of galantamine.
Clin Pharmacokinet., 42(15):1383-92 (2003)
Update on rivastigmine.
Neurologist., Sep;9(5):230-4 (2003)